Addiction Medicine
🔒 Full Review for Subscribers Practice Signal Addiction Medicine Confirmatory Grade: Moderate
All three FDA-approved medications for opioid use disorder are effective, but buprenorphine-naloxone offers a modest edge in overdose prevention, and treatment continuity plus harm reduction matter more than agent choice alone.
Ambulatory Care / MTM
🔒 Full Review for Subscribers Practice Signal Ambulatory Care / MTM Confirmatory Grade: Low
Across community strep testing, emergency department culture callbacks, post-discharge result review, and remote blood pressure management, pharmacist prescribing under protocols shows consistent process gains, but the evidence is low certainty, outcome benefit is unproven, and success depends more on infrastructure, triage rules, and patient follow-through than on pharmacist clinical willingness.
Cardiology
🔓 Free Sample Practice Signal Cardiology Practice-changing Grade: High
The 2026 dyslipidemia guideline restores absolute LDL-C targets and permits non-sequential nonstatin selection while expanding statin eligibility to roughly 87.5 million US adults, so pharmacists should prepare for more shared decision-making, absolute-risk counseling, and earlier use of PCSK9 inhibitors, inclisiran, and bempedoic acid. Since publication, STAREE added the first placebo-controlled outcome data in healthy adults 70 and older (major cardiovascular events HR 0.70, no gain in disability-free survival), and Lp(a)HORIZON missed its primary endpoint, so Lp(a) stays a risk enhancer rather than a treatment target.
🔒 Full Review for Subscribers Practice Signal Cardiology Practice-changing Grade: Moderate
In atrial fibrillation, the anticoagulation risk-benefit calculus now hinges on drug-specific reversal (idarucizumab for dabigatran, off-label four-factor prothrombin complex concentrate as the pragmatic default for factor Xa inhibitors after andexanet's withdrawal) and on left atrial appendage closure as a bleeding-sparing but not stroke-superior alternative in selected patients.
🔒 Full Review for Subscribers Practice Signal Cardiology Practice-changing Grade: High
Factor XI/XIa inhibitors are moving from clinical trials to regulatory review, with asundexian now the first molecule in this class under FDA priority review for US market approval. OCEANIC-STROKE demonstrated a 26% reduction in recurrent ischemic stroke (HR 0.74, P<0.001) without increased major bleeding when added to antiplatelet therapy in 12,327 patients with noncardioembolic stroke or high-risk TIA. The class includes two oral FXIa inhibitors (asundexian, milvexian) and one subcutaneous anti-FXI monoclonal antibody (abelacimab), each pursuing different indications with different results. Asundexian failed in atrial fibrillation (OCEANIC-AF terminated early, HR 3.79 for stroke vs apixaban), and milvexian added to antiplatelet therapy after acute coronary syndrome did not reduce cardiovascular death, MI or ischemic stroke in LIBREXIA ACS (HR 1.05; 95% CI 0.91-1.21). Milvexian and abelacimab AF trials remain ongoing, but so far the class has one proven home: secondary prevention after noncardioembolic stroke. For acute care pharmacists, the practical question is no longer whether FXIa inhibition works, but how to build formulary frameworks for a drug that looks like an anticoagulant, acts on the coagulation cascade, yet has a bleeding profile indistinguishable from placebo.
Clinical Pharmacokinetics
🔒 Full Review for Subscribers Practice Signal Clinical Pharmacokinetics Confirmatory Grade: Low
Across ICU vancomycin, pediatric vancomycin population pharmacokinetic (popPK) modeling, and pediatric tacrolimus, target attainment depends as much on monitoring infrastructure, model selection, and human-factor interventions as on the drug concentration itself.
Critical Care
🔒 Full Review for Subscribers Practice Signal Critical Care Confirmatory Grade: Low
Across these sources, the strongest practice signal is still early, appropriately selected antibiotics followed by structured reassessment (stewardship time-outs, time-limited inotrope trials), while early multi-vasopressor strategies remain investigational and should not displace the stepwise Surviving Sepsis Campaign (SSC) vasopressor sequence.
🔒 Full Review for Subscribers Practice Signal Critical Care Practice-changing Grade: High
Antipsychotics do not resolve ICU delirium, shorten hospitalization, or improve survival. Large randomized trials of haloperidol and ziprasidone (MIND-USA, AID-ICU) and of prophylactic haloperidol (REDUCE), two meta-analyses, and the 2025 PADIS guideline update converge on the same conclusion: haloperidol, ziprasidone, and atypical antipsychotics lack efficacy as delirium treatments in critically ill patients. Pharmacists should challenge reflexive antipsychotic orders for ICU delirium and instead champion the ABCDEF bundle, reserving antipsychotics only for brief management of severe agitation that threatens patient safety.
Emergency / Critical Care
🔒 Full Review for Subscribers Practice Signal Emergency / Critical Care Hypothesis-generating Grade: Low
For extracranial warfarin and factor Xa inhibitor major bleeding, fixed-dose four-factor prothrombin complex concentrate (4F-PCC) is a reasonable, faster, and more resource-sparing default when paired with a repeat-dose pathway, while weight and international normalized ratio (INR) based dosing remains preferred for vitamin K antagonist associated intracranial hemorrhage.
Endocrinology / Obesity
🔒 Full Review for Subscribers Practice Signal Endocrinology / Obesity Practice-changing Grade: High
Across obesity, cardiovascular disease, heart failure with preserved ejection fraction, chronic kidney disease, metabolic dysfunction-associated steatohepatitis, and even alcohol use disorder, GLP-1 receptor agonist (GLP-1RA) benefit tracks the patient's comorbid disease profile more than any BMI threshold, and pharmacists should frame these agents as indefinite, disease-targeted chronic therapy.
🔒 Full Review for Subscribers Practice Signal Endocrinology / Obesity Practice-changing Grade: High
Most patients on once-weekly icodec or efsitora can stay on their weekly dose through a routine admission: in trial hospitalizations 97.8% of icodec cases needed no added daily basal insulin and glucose control was stable before and after. Confirm the last dose date and weekly units, cover meals and corrections instead of stacking a daily basal dose, and plan elective major surgery weeks ahead, because a weekly dose cannot be taken back.
Geriatrics / Polypharmacy
🔓 Free Sample Practice Signal Geriatrics / Polypharmacy Practice-changing Grade: Moderate
Pharmacist-led medication review and embedded decision-support algorithms reliably reduce inappropriate prescribing in older adults, and newer transition-of-care and N-of-1 approaches are beginning to link deprescribing to hard outcomes like readmission, but consistent downstream mortality or symptom benefit remains unproven.
🔒 Full Review for Subscribers Practice Signal Geriatrics / Polypharmacy Practice-changing Grade: High
For a robust adult over 70 without cardiovascular disease, atorvastatin 40 mg prevents heart attacks and revascularizations (STAREE: HR 0.70, NNT 37 over about 6 years) but does not preserve independence, cognition or survival. For an adult 75 or older already taking a primary-prevention statin, stopping did not raise 3-year mortality in the only randomized trial (SAGA/SITE), but it brought no symptom or quality-of-life benefit either. Age alone is not a reason to start, stop or withhold a statin; prognosis, function and the patient's goals are.
GI/Hepatology
🔒 Full Review for Subscribers Practice Signal GI/Hepatology Practice-changing Grade: High
For noncirrhotic MASH with F2-F3 fibrosis, two agents are now FDA-approved with high-quality histologic evidence, resmetirom (a liver-targeted THR-beta agonist) and semaglutide 2.4 mg (a metabolically active GLP-1 receptor agonist), and pharmacists can guide selection using noninvasive test thresholds, comorbidity fit, and drug-interaction and monitoring profiles.
Heart Failure
🔓 Free Sample Practice Signal Heart Failure Practice-changing Grade: High
Full four-pillar guideline-directed medical therapy remains the foundation for heart failure with reduced ejection fraction, and finerenone now extends disease-modifying options into the mildly reduced and preserved ejection fraction range, but the persistent gap is implementation in the highest-risk patients rather than a lack of proven therapies.
Infectious Disease / Antimicrobials
🔓 Free Sample Practice Signal Infectious Disease / Antimicrobials Practice-changing Grade: Low
Antimicrobial stewardship that changes prescribing depends on active, patient-specific, pharmacist-delivered interventions (audit and feedback, time-outs, dose individualization) rather than passive alerts or education alone.
🔒 Full Review for Subscribers Practice Signal Infectious Disease / Antimicrobials Practice-changing Grade: Moderate
Cefepime carries a small, inconsistent adult mortality signal that is best handled through renal-appropriate dosing, neurotoxicity surveillance, and exposure control with therapeutic drug monitoring (TDM) rather than by abandoning the drug, because the main alternative, piperacillin-tazobactam, has its own unresolved mortality questions.
Medication Safety
🔒 Full Review for Subscribers Practice Signal Medication Safety Hypothesis-generating Grade: Low
Across renal dosing, anticoagulant screening, and intensive care unit (ICU) interaction alerting, clinical decision support systems (CDSS) reliably surface prescribing problems but have no proven effect on clinical outcomes, so their value depends on pharmacist triage, alert stratification, and local implementation quality.
Nephrology / Cardiorenal
🔒 Full Review for Subscribers Practice Signal Nephrology / Cardiorenal Practice-changing Grade: High
Finerenone now has randomized evidence for cardiorenal protection across type 2 diabetic and non-diabetic albuminuric chronic kidney disease (CKD), and should be considered as an add-on to maximally tolerated renin-angiotensin system (RAS) blockade with a structured potassium monitoring plan rather than reserved for advanced disease.
Neurology
🔒 Full Review for Subscribers Practice Signal Neurology Confirmatory Grade: Low
Subcutaneous continuous drug delivery, whether foslevodopa/foscarbidopa for Parkinson OFF time or subcutaneous natalizumab for multiple sclerosis, offers durable disease control or major operational and experience gains, shifting the pharmacist's role toward infusion-site care, dose reconciliation, and patient selection.
🔒 Full Review for Subscribers Practice Signal Neurology Practice-changing Grade: High
Imaging-based selection now extends intravenous thrombolysis to 9 hours and wake-up stroke, and tenecteplase has become an equal first-line agent to alteplase within 4.5 hours, but adding a late-window lytic on top of thrombectomy in perfusion-selected large-vessel occlusion has not improved functional outcomes.
🔒 Full Review for Subscribers Practice Signal Neurology Confirmatory Grade: Moderate
In atrial fibrillation after intracerebral hemorrhage, every randomized trial points the same way: a DOAC prevents ischemic strokes and causes more brain bleeds. PRESTIGE-AF cut ischemic stroke from 8.60 to 0.83 per 100 patient-years but raised recurrent ICH from 0.82 to 5.00, and ENRICH-AF (ESC 2026) found no reduction in stroke or embolism with edoxaban in unselected patients. Restarting is a shared decision driven by the bleed's phenotype: most defensible after deep, hypertension-related ICH with blood pressure controlled, and hardest to justify after lobar ICH or suspected cerebral amyloid angiopathy.
🔒 Full Review for Subscribers Practice Signal Neurology Practice-changing Grade: High
Plasma p-tau217 blood tests can identify Alzheimer's disease pathology with accuracy approaching PET and CSF, but they detect amyloid status, not cognitive decline. Current guidelines restrict their use to specialty settings with objective cognitive impairment, yet direct-to-consumer tests and primary care ordering are already outpacing the evidence. Pharmacists should be prepared to counsel patients on what these results do and do not mean, flag false-positive risk in patients with severe renal impairment (eGFR 30 or below), and understand that a positive result does not equal a dementia diagnosis.
Oncology
🔒 Full Review for Subscribers Practice Signal Oncology Practice-changing Grade: Moderate
In previously treated RAS-mutated metastatic pancreatic cancer, oral daraxonrasib doubled median overall survival versus chemotherapy (hazard ratio [HR] 0.40), making pan-RAS inhibition a likely new second-line standard once RAS status is confirmed.
Oncology Pharmacy
🔒 Full Review for Subscribers Practice Signal Oncology Pharmacy Confirmatory Grade: Moderate
Programmed cell death 1 and programmed death-ligand 1 (PD-1/PD-L1) inhibitor benefit in triple-negative breast, cervical, and resectable head and neck cancers depends on disease setting, PD-L1 selection, and the exact trial regimen, while rechallenge after an immune-related adverse event (irAE) carries roughly a one-in-five risk of grade 3 or higher toxicity and calls for deliberate counseling.
🔒 Full Review for Subscribers Practice Signal Oncology Pharmacy Practice-changing Grade: High
PD-1/PD-L1 checkpoint inhibitors have moved from metastatic salvage to validated first-line and adjuvant use across GI and liver cancers, but the strength of evidence and the role of the chemotherapy backbone differ sharply by tumor type and treatment setting.
Psychiatry
🔒 Full Review for Subscribers Practice Signal Psychiatry Confirmatory Grade: Low
Attention-deficit/hyperactivity disorder (ADHD) carries a consistent excess mortality signal driven largely by suicide and injury, so pharmacists can support treatment engagement and pair any stimulant or nonstimulant choice, including the d-amphetamine transdermal system (d-ATS) or viloxazine extended-release (ER), with structured suicidality, comorbidity, and cardiovascular monitoring, while not overstating the observational link between medication and survival.
🔒 Full Review for Subscribers Practice Signal Psychiatry Confirmatory Grade: Moderate
Intranasal esketamine is now supported by controlled data as monotherapy for treatment-resistant depression (TRD), while oral ketamine and esketamine formulations remain investigational and should not displace guideline-supported routes.